The Food and Drug Administration granted de novo approval to Modius Spero, marking it the world’s first neuromodulation device authorized to treat symptoms associated with post-traumatic stress disorder.
The wearable device was developed by Neurovalens and uses low-level electrical stimulation to target specific areas of the brain associated with PTSD symptoms, according to a May 26 news release from the company. The approval followed a U.S. clinical trial of 383 adults with clinical PTSD diagnoses.
The FDA’s de novo pathway is a risk-based classification process for novel medical devices that lack a legally marketed predicate.
In the study, participants received either the Modius Spero headset or an active sham device. Two-thirds of participants using Modius Spero reported a “clinically meaningful improvement in PTSD symptoms,” according to the release
The device is designed for adults ages 22 and older and delivers 30-minute daily sessions of noninvasive nerve stimulation prescribed and overseen by a healthcare professional as part of a broader treatment plan.
Neurovalens said Modius Spero will become available to veterans through the U.S. Department of Veterans Affairs “from this summer onwards,” according to the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
